| Audience | Cannabis patients who are parents or caregivers, pediatricians, emergency clinicians, dispensary staff, and cannabis policymakers |
| Primary Topic | unintentional pediatric ingestion of recreational drugs, overwhelmingly cannabis edibles, reported to United States poison centers from 2000 through 2024 |
| Source | Read the study in BMC Public Health |
Pediatric Cannabis Poisoning Calls Rose 3,307% in 25 Years, National Data Show
A 25-year analysis of United States poison center calls found that unintentional ingestions of recreational drugs among children younger than 6 rose 3,307 percent since 2000, overwhelmingly driven by cannabis edibles. Most exposures were mild, but 5 percent were severe and six children died.
Cannabis medicine has real, evidence-backed applications, and expanding legal access has helped many patients. That expansion has also changed what sits on kitchen counters and in nightstand drawers in millions of homes, often in the form of gummies, chocolates, and beverages that a toddler cannot distinguish from candy or juice.
A new 25-year national analysis puts a number on that shift. Unintentional pediatric ingestions of recreational drugs, mostly cannabis edibles, have climbed steadily and then sharply since 2013. This is not an argument against cannabis as medicine. It is a direct, practical safety issue that deserves the same plain, unembarrassed counseling clinicians already give about medication lockboxes and detergent pods.
| Study Type | Retrospective cohort study of National Poison Data System (NPDS) call records |
| Study Period | 2000 through 2024 (25 years) |
| Population | Children younger than 6 years in the United States |
| Total Cases | 41,612 unintentional ingestions of recreational drugs |
| Rate Change | Ingestion rate per 100,000 children rose 3,307%, from 1.05 in 2000 to 35.91 in 2024 |
| Inflection Point | Rapid acceleration beginning in 2013, especially edible marijuana and psilocybin products |
| Substance Breakdown | Cannabinoids 84.7%, stimulants 8.4%, psychedelics 3.5%, opioids 2.8%, dissociative agents 0.6% |
| Age Pattern | 57.6% of children were younger than 3 years |
| Setting and Substance Count | 96.4% occurred in a residence; 95.9% involved a single substance |
| Medical Outcomes | 50.6% no or minor effect; 5.0% major effect; 6 deaths |
| Highest Critical-Care Risk by Substance | Opioids (RR 2.60, 95% CI 2.36-2.86), stimulants (RR 2.16, 95% CI 2.01-2.31), and dissociative agents (RR 1.59, 95% CI 1.23-2.06) versus other categories combined |
| Age-Related Risk | Children under 3 had higher rates of major effect (RR 1.54, 95% CI 1.39-1.71) and critical care admission (RR 1.23, 95% CI 1.16-1.30) than children 3-5 |
| Data Sources | National Poison Data System (America’s Poison Centers) and U.S. Census Bureau population estimates |
| Journal | BMC Public Health |
| Published | June 24, 2026 |
| Authors | Uskovich, Hays, Badeti, Rine, Michaels, Ding, and Smith (Nationwide Children’s Hospital and Central Ohio Poison Center) |
The population-adjusted rate of unintentional recreational-drug ingestions among children under 6 was essentially flat and low through the early 2000s, at roughly 1 case per 100,000 children in 2000. It began climbing steadily and then sharply after 2013, reaching 35.91 per 100,000 children by 2024, a 3,307 percent increase over the full study period.
The authors specifically identify edible marijuana and psilocybin products as the categories driving the post-2013 acceleration, a period that overlaps closely with the expansion of state legal and medical cannabis markets and, more recently, some jurisdictions’ psilocybin programs.
Cannabinoids accounted for 84.7 percent of all 41,612 ingestions, far outweighing stimulants (8.4 percent), psychedelics (3.5 percent), opioids (2.8 percent), and dissociative agents (0.6 percent). Given how much more common cannabinoid exposures were, they also account for the large majority of major-effect cases and deaths in absolute terms.
Notably, when the analysis compared relative risk of critical care admission by substance category, opioids, stimulants, and dissociative agents each carried a higher relative risk than cannabinoids, even though cannabinoids caused far more total ingestions. Frequency and severity risk are two different questions, and this study lets us examine both.
Children younger than 3 accounted for 57.6 percent of all cases and were significantly more likely than children aged 3 to 5 to experience a major medical effect (RR 1.54, 95% CI 1.39-1.71) or be admitted to a critical care unit (RR 1.23, 95% CI 1.16-1.30). Nearly all exposures, 96.4 percent, occurred inside a residence, and 95.9 percent involved only a single substance, consistent with a young child finding and eating an accessible product rather than deliberate co-ingestion.
These are precisely the children least able to recognize a cannabis edible as anything other than food, and least able to communicate what they ingested or when.
The study’s authors point to opaque, child-resistant packaging with limits on total dose per package and per serving, single-serving packaging, and clear labeling as concrete manufacturer- and policy-level interventions. These recommendations track closely with existing pediatric poisoning-prevention frameworks used for medications and household chemicals.
At the household level, the clearest actionable step remains simple: store all cannabis products, especially edibles, the way a family would store a prescription medication, up, away, out of sight, and ideally in a locked container, never in a location a young child can reach independently.
The rise in edible-driven pediatric exposures parallels the broader commercialization of cannabis products, many of which are intentionally formulated and packaged to resemble familiar candies, baked goods, and beverages. That design choice, appealing to adult consumers, is precisely what makes these products indistinguishable from food to a toddler.
This tension sits at the center of responsible cannabis medicine: expanding legitimate, evidence-based adult access while treating pediatric exposure prevention as a nonnegotiable clinical and regulatory priority, not an afterthought. Physicians who recommend or manage cannabis therapy for patients with children in the home have a direct role in closing that gap through routine, specific storage counseling.
In two decades of clinical cannabis practice, the question I ask nearly every patient who is also a parent or grandparent is not whether they use cannabis responsibly, but where the product physically lives in their home when they are not looking at it. This study puts hard numbers behind an instinct many of us in this field have had for years: as edibles became more common and more candy-like, pediatric exposures became a real and rising problem.
None of this argues against cannabis as medicine. It argues for treating storage the way we already treat opioids, benzodiazepines, and anything else in a childproof cabinet, as a routine, unembarrassed part of the clinical conversation rather than something raised only after an incident.
How to Read a Pediatric Poisoning Trend Study
A dramatic percentage increase can be true and still need context about baseline rates, case definitions, and what the underlying data source can and cannot capture.
These checks help keep a population surveillance finding useful without overstating what it proves about any individual family.
A Four-Step Reading Frame
Check the baseline
A 3,307 percent increase sounds enormous partly because the starting rate in 2000 was very low (about 1 per 100,000); the 2024 rate of roughly 36 per 100,000 is the number that matters for absolute risk.
Separate frequency from severity
Cannabinoids caused the most ingestions, but opioids, stimulants, and dissociative agents carried higher relative risk of critical care admission per ingestion.
Know what the data source can see
National Poison Data System calls depend on someone recognizing and reporting an exposure; unreported or unrecognized ingestions are not captured.
Hold the policy question separately
The study documents a national trend correlated with the post-2013 period of market expansion; it does not test state-by-state legalization status as a variable.
Eight Ways to Read a Pediatric Cannabis Poisoning Trend
A clinical, caregiver, and public health reading of a 25-year national poison center dataset
This Is a Storage Problem, Not a Verdict on Your Cannabis Use
If you use cannabis medically or recreationally and have young children or grandchildren in your home, this study is directly about you, but not as a judgment. It is a data-backed reminder that edible products, precisely because they are formulated to taste and look appealing, are functionally indistinguishable from food to a child under 3.
The practical response is concrete rather than abstract: treat edibles exactly as you would a prescription medication bottle. Store them in a location a young child cannot reach without help, ideally in a locked container, and never leave an open package on a counter, nightstand, or purse even briefly.
Ask About Storage the Way You Ask About Firearm Safety
Given that cannabinoids caused 84.7 percent of the 41,612 ingestions in this cohort, and that most occurred at home in children under 3, clinicians who recommend or manage cannabis therapy for adults with young children or grandchildren in the household have a specific, evidence-supported reason to raise storage explicitly at every visit, not only at intake.
This can be a brief, nonjudgmental script: confirm what forms of cannabis are in the home, confirm where they are stored, and confirm whether a young child has independent access to that location. This mirrors well-established counseling patterns for firearms, medications, and household chemicals.
Children Under 3 Are the Highest-Risk Group, by a Meaningful Margin
Children younger than 3 made up 57.6 percent of all cases and had significantly higher rates of major medical effects and critical care admission than children age 3 to 5. This age group is old enough to explore its environment and put things in its mouth, but too young to recognize danger or reliably tell an adult what happened.
This pattern should sharpen where prevention counseling focuses. A family with a mobile, exploratory toddler under 3 is at meaningfully higher risk than a family with only older children, and storage guidance should be delivered with that specific age window in mind.
Edible Formats Are Doing Most of the Work in This Trend
The study authors specifically flag edible marijuana and psilocybin products as the categories behind the post-2013 acceleration. This lines up with a broader, well-documented pattern in which legal cannabis markets have leaned heavily into gummies, chocolates, baked goods, and beverages that closely resemble ordinary snack foods and drinks.
Manufacturer-level interventions the authors highlight, opaque and child-resistant packaging, per-package and per-serving dose limits, single-serving packaging, and clear labeling, are not new ideas in pediatric poisoning prevention. They are the same basic tools already applied to medications, and this data set is a direct argument for applying them more consistently to cannabis edibles.
A Striking Percentage Increase Still Needs Its Denominator
A 3,307 percent increase is the kind of figure that can be used to alarm rather than inform. It is accurate, but it is calculated from a very small 2000 baseline of about 1 case per 100,000 children, so the more clinically useful number is the 2024 rate itself, roughly 36 cases per 100,000 children under 6, alongside the absolute case count of 41,612 over 25 years.
It is also worth noting explicitly that poison center data reflects reported and recognized exposures only. Ingestions that a caregiver did not notice, or noticed but did not report, are invisible to this data source in either direction, and the true underlying exposure rate cannot be determined from this study alone.
Severity Clustered in a Recognizable Pattern
About half of children, 50.6 percent, had no or only minor effects, but 5.0 percent experienced a major effect and six children died over the 25-year study period. Critical care admission was significantly more likely for children under 3 and for ingestions involving opioids, stimulants, or dissociative agents specifically, even though those substances were far less common overall than cannabinoids.
For emergency clinicians, this supports maintaining a broad differential and a low threshold for toxicology and observation in a young child presenting with an unexplained altered mental status or lethargy, particularly when a cannabis product cannot be ruled out as present in the home.
The Trend Argues for Packaging Standards, Not for Reversing Legal Access
The timing of the post-2013 acceleration alongside cannabis market expansion is a real and worth-noting association, but this study does not test state-level legalization status directly, so it cannot be used to claim that legal access itself, rather than product design, marketing, or awareness, is the specific driver.
The more directly supported policy response is the one the authors themselves propose: opaque and child-resistant packaging, serving and package dose limits, single-serving formats, and clear labeling requirements, applied consistently across legal cannabis markets rather than varying widely by state.
Full-Text Review and State-Level Analysis Would Sharpen This Picture
This review relied on the peer-reviewed abstract and indexed study metadata; the full paper was not available for detailed review of methodology, exact case definitions, or state-level subgroup data at the time this article was written. A closer read of the full text would help confirm details such as exact THC dose data where available and any state-by-state breakdown.
Future research that links this national trend to specific state legalization timelines, packaging-regulation changes, and product-level THC content would help clarify how much of the increase reflects policy, product design, or reporting behavior, and would sharpen exactly which interventions are working where they have already been tried.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this new study find about pediatric cannabis poisoning?
A 25-year U.S. poison center study found unintentional ingestions of recreational drugs among children under 6 rose 3,307 percent from 2000 to 2024, with cannabinoids, mostly edible products, accounting for 84.7 percent of the 41,612 cases identified.
How many children were affected?
The study identified 41,612 unintentional ingestions of recreational drugs among children younger than 6 reported to United States poison centers between 2000 and 2024.
Which age group is most at risk?
Children younger than 3 accounted for 57.6 percent of cases and had significantly higher rates of major medical effects and critical care admission than children ages 3 to 5.
Is cannabis really the main substance involved?
Yes. Cannabinoids accounted for 84.7 percent of all ingestions, far more than stimulants (8.4 percent), psychedelics (3.5 percent), opioids (2.8 percent), or dissociative agents (0.6 percent).
Were these exposures serious?
Just over half of children, 50.6 percent, had no or only minor effects, but 5.0 percent experienced a major medical effect, and there were six deaths over the 25-year study period.
Why did cases increase so sharply after 2013?
The study authors point to rapid growth in edible marijuana and psilocybin products beginning around 2013, a period that overlaps with expanding legal cannabis markets, though the study did not directly test state legalization status as a cause.
Does this mean cannabis is more dangerous than other recreational drugs?
Not necessarily by every measure. While cannabinoids caused the most total ingestions, opioids, stimulants, and dissociative agents each carried a higher relative risk of critical care admission per ingestion than cannabinoids.
What should parents and caregivers who use cannabis do?
Store all cannabis products, especially edibles, the way you would store a prescription medication: up, away, out of sight, and ideally in a locked container that a young child cannot access independently.
What packaging changes do the study authors recommend?
They recommend opaque, child-resistant packaging with limits on total dose per package and per serving, single-serving formats, and clear labeling to reduce the risk of accidental ingestion by young children.
Where did this data come from?
Researchers analyzed 25 years of calls to the National Poison Data System, maintained by America's Poison Centers, and used U.S. Census Bureau data to calculate population-based ingestion rates.
